Amneal Pharmaceuticals Stock

Amneal Pharmaceuticals Liabilities 2024

Amneal Pharmaceuticals Liabilities

3.45 B USD

Ticker

AMRX

ISIN

US03168L1052

WKN

A2JLMD

In 2024, Amneal Pharmaceuticals's total liabilities amounted to 3.45 B USD, a -1.37% difference from the 3.5 B USD total liabilities in the previous year.

Amneal Pharmaceuticals Aktienanalyse

What does Amneal Pharmaceuticals do?

Amneal Pharmaceuticals Inc is a leading pharmaceutical company headquartered in Bridgewater, New Jersey, USA. It was founded in 2002 by Chirag Patel and Chintu Patel, both of whom were involved in the generic pharmaceutical industry. Amneal specializes in the development, manufacturing, and marketing of high-quality, cost-effective generic and specialty pharmaceuticals for a variety of therapeutic areas. The company's mission is to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal operates globally in over 50 countries, with global facilities in India, Ireland, and other countries. The company strives to provide innovation, exceptional service, and reliability to customers and patients worldwide. Over the years, the company has rapidly grown to become a major player in the global pharmaceutical market. It offers a wide range of products, including both generic and specialty pharmaceuticals in numerous therapy areas. These areas include oncology, central nervous system (CNS), gastroenterology, dermatology, immunology, pain management, and many others. Amneal places a strong emphasis on clinical research and development to create innovative medications and therapies that meet the needs of today's patients. The company has multiple research and development centers worldwide, including in Israel, India, and the USA, where it collaborates closely with industry partners to develop new products. Another hallmark of Amneal is its ability to provide high-quality generic pharmaceuticals that meet the needs of customers in different countries and regions. The company manufactures its products to the highest standards and has a strict quality assurance system to ensure that patients can rely on receiving medications of the highest quality and efficacy. Amneal's product line is extensive, encompassing a variety of drugs ranging from simple over-the-counter (OTC) preparations to complex steroids and oncology therapeutics. Some of its key products include Tamoxifen Citrate, Lamotrigine, Methylphenidate Hydrochloride, Warfarin Sodium, Buprenorphine-Naloxone, and many others. Amneal Pharmaceuticals also forms partnerships with other companies to expand and diversify its business model. In 2018, Amneal merged with Impax Laboratories, Inc., a leading pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty products for various therapy areas. The merger brought together both companies, creating an entity with a broader product portfolio, a larger global reach, and stronger development and marketing expertise. In summary, Amneal Pharmaceuticals Inc is a leading pharmaceutical company focused on the development and marketing of generic and specialty pharmaceuticals for a variety of therapeutic areas. The company is on a mission to help patients worldwide by producing and delivering high-quality, cost-effective medications. Amneal prioritizes clinical research and development to create innovative medications and therapies, and it has a strict quality assurance system. The company has a wide product range and collaborates closely with other companies to expand its business model and global reach. Amneal Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Amneal Pharmaceuticals's Liabilities

Amneal Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Amneal Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Amneal Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Amneal Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Amneal Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Amneal Pharmaceuticals stock

What is the level of liabilities of Amneal Pharmaceuticals this year?

Amneal Pharmaceuticals has a debt balance of 3.45 B USD this year.

What were the liabilities of Amneal Pharmaceuticals compared to the previous year?

The liabilities of Amneal Pharmaceuticals have increased by -1.37% dropped compared to the previous year.

What are the consequences of high debt for investors of Amneal Pharmaceuticals?

High liabilities can pose a risk for investors of Amneal Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Amneal Pharmaceuticals?

Low liabilities mean that Amneal Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Amneal Pharmaceuticals affect the company?

An increase in liabilities of Amneal Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Amneal Pharmaceuticals affect the company?

A decrease in the liabilities of Amneal Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Amneal Pharmaceuticals?

Some factors that can influence the liabilities of Amneal Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Amneal Pharmaceuticals so important for investors?

The liabilities of Amneal Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Amneal Pharmaceuticals take to modify the liabilities?

To change its liabilities, Amneal Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Amneal Pharmaceuticals pay?

Over the past 12 months, Amneal Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amneal Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Amneal Pharmaceuticals?

The current dividend yield of Amneal Pharmaceuticals is .

When does Amneal Pharmaceuticals pay dividends?

Amneal Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amneal Pharmaceuticals?

Amneal Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Amneal Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amneal Pharmaceuticals located?

Amneal Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amneal Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amneal Pharmaceuticals from 10/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/14/2024.

When did Amneal Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/14/2024.

What was the dividend of Amneal Pharmaceuticals in the year 2023?

In the year 2023, Amneal Pharmaceuticals distributed 0 USD as dividends.

In which currency does Amneal Pharmaceuticals pay out the dividend?

The dividends of Amneal Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Amneal Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Amneal Pharmaceuticals

Our stock analysis for Amneal Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amneal Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.